Related Experiment Video
Updated: Nov 24, 2025
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
853
Dose-response for yttrium-90 resin microsphere radioembolisation.
1Department of Nuclear Medicine, The Royal Melbourne Hospital, Victoria, Australia.
Nuclear Medicine Communications
|December 21, 2020
Summary
Yttrium-90 radioembolisation for liver cancer requires balancing safety and efficacy through dose-response data. This study tabulates key metrics to guide treatment, optimizing outcomes for patients with liver malignancies.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Yttrium-90 radioembolisation is a key treatment for liver malignancies.
- Balancing treatment safety and efficacy is crucial for patient outcomes.
- Effective treatment requires robust dose-response guidance.
Purpose of the Study:
- To provide a comprehensive tabulation of published dose-response metrics for Yttrium-90 resin microsphere radioembolisation.
- To establish clear dose-response guidance for liver malignancy treatment.
- To aid clinicians in optimizing Yttrium-90 radioembolisation therapy.
Main Methods:
- Systematic review and tabulation of published data.
- Inclusion of key dose-response metrics: mean absorbed dose (Gy), dose-volume histograms, Biologically Effective Doses (BED), Normal Tissue Complication Probability (NTCP), and Tumour Control Probability (TCP).
Main Results:
- Compilation of critical dose-response data for Yttrium-90 radioembolisation.
- Presentation of metrics to inform treatment planning and safety assessments.
- Data supports the development of evidence-based clinical protocols.
Conclusions:
- Accurate dose-response data is fundamental for safe and effective Yttrium-90 radioembolisation.
- This tabulation serves as a valuable resource for clinicians and researchers.
- Optimized dosimetry can improve therapeutic ratios in liver cancer treatment.
Related Concept Videos
01:03Dose-Response Relationship: Overview
4.5K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.5K
01:22Dose-Response Relationship: Potency and Efficacy
6.0K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.0K